Transcera

Transcera is a venture-backed biotechnology company based in Cambridge, Massachusetts, focused on developing a proprietary platform for extracellular protein degradation. The company's technology utilizes novel sphingolipid biology to direct proteins into lysosomes for degradation. By combining a lysosome-targeting lipid with a tunable chemical linker and a protein or peptide binder, the platform creates compact, manufacturable molecules capable of targeting both soluble and membrane proteins across various tissues. This approach, derived from research at Harvard Medical School and Boston Children’s Hospital, aims to provide a more effective method for degrading disease-driving proteins compared to traditional receptor-mediated approaches.

The company's platform addresses challenges in treating chronic diseases by enabling potent, selective, and systemic degradation of extracellular targets. Its technology has demonstrated the ability to cross intestinal epithelial barriers, offering potential for the oral delivery of biologics and improved pharmacokinetic properties. By targeting aberrant extracellular biology, Transcera seeks to transform the therapeutic landscape for immune, metabolic, and endocrine disorders. The company, which is backed by investors including Digitalis Ventures, Pear VC, KdT Ventures, and Xora Innovation, is currently advancing a pipeline of degraders and building its internal expertise in chemistry, cellular biology, and preclinical development.